Senti Biosciences, Inc. (NASDAQ:SNTI - Get Free Report)'s share price traded up 2.5% on Thursday . The company traded as high as $2.34 and last traded at $2.27. 113,805 shares changed hands during mid-day trading, a decline of 83% from the average session volume of 653,933 shares. The stock had previously closed at $2.21.
Analyst Ratings Changes
A number of research analysts recently weighed in on the stock. Laidlaw assumed coverage on shares of Senti Biosciences in a research report on Friday, June 6th. They issued a "buy" rating and a $5.00 target price for the company. Chardan Capital reaffirmed a "buy" rating and issued a $12.00 target price on shares of Senti Biosciences in a research report on Thursday, June 12th.
Get Our Latest Research Report on SNTI
Senti Biosciences Stock Performance
The business's 50-day moving average price is $2.89 and its 200 day moving average price is $3.50. The company has a market cap of $57.64 million, a P/E ratio of -0.20 and a beta of 2.09.
Senti Biosciences (NASDAQ:SNTI - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($1.41) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.85). The firm had revenue of $1.30 million for the quarter, compared to the consensus estimate of $1.30 million. Equities research analysts forecast that Senti Biosciences, Inc. will post -14.54 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of SNTI. Virtu Financial LLC bought a new position in shares of Senti Biosciences in the 4th quarter valued at about $47,000. Renaissance Technologies LLC acquired a new stake in shares of Senti Biosciences during the 4th quarter worth about $181,000. Heights Capital Management Inc. acquired a new stake in shares of Senti Biosciences during the 1st quarter worth about $2,520,000. Finally, Nantahala Capital Management LLC acquired a new stake in shares of Senti Biosciences during the 1st quarter worth about $2,984,000. Institutional investors own 25.73% of the company's stock.
About Senti Biosciences
(
Get Free Report)
Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.
Read More
Before you consider Senti Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Senti Biosciences wasn't on the list.
While Senti Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
